TSHA

Over the past six months (March 2026 - September 2026), Taysha Gene Therapies experienced several significant stock events. In May 2026, the company appointed a new Chief Financial Officer and Chief Operating Officer, and reported its first-quarter financial results. June 2026 saw an announcement of a proposed public offering of common stock and pre-funded warrants, equity awards granted to new employees, and presentations of clinical and preclinical data at a scientific meeting. In July 2026, Taysha was dropped from several Russell indexes, though its share price performance remained strong with 30-day and 90-day returns of 22.57% and 46.33% respectively, and it completed a $230 million equity offering, extending its cash runway into the second half of 2028. August 2026 included an expanded strategic partnership with Catalent for future commercial manufacturing of TSHA-102, the reporting of second-quarter financial results with a widened net loss, and additional inducement grants to new employees. In September 2026, another inducement grant was announced, Wolfe Research initiated coverage with an 'outperform' rating, and analysts increased price targets, suggesting a potential upside of approximately 147.5% from its price of $5.16.